Lexaria Bioscience Corp. (LEXX)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Aug 31
In fiscal 2025, Lexaria Bioscience Corp. reported revenue of $705.9K, up 52.0% from the prior year. The company ran a net loss, with a net margin of -1686.0% and a gross margin of 99.6%. It held $4.18M in total assets against $1.57M in total liabilities.
Key ratios (FY2025)
99.6%
Gross margin
-1683.0%
Operating margin
-1686.0%
Net margin
-398.1%
Return on equity
+52.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $705.9K | $464.3K | $226.2K | $255.4K | $722.7K | $314.8K | — | — | — | — |
| Cost of Revenue | $2.7K | $4.8K | $31.5K | $71.8K | $175.3K | $99.4K | $22.9K | $25.2K | $29.8K | $45.6K |
| Gross Profit | $703.2K | $459.5K | $194.7K | $183.6K | $547.4K | $215.4K | $199.7K | $408.1K | $33.9K | -$4.9K |
| Operating Income | -$11.88M | -$5.75M | -$6.53M | -$6.62M | -$5.69M | — | — | — | — | -$1.28M |
| Net Income | -$11.90M | -$5.80M | -$6.66M | -$7.27M | -$4.03M | -$4.08M | -$4.16M | -$6.61M | -$1.93M | -$1.28M |
| EPS (Diluted) | $-0.66 | $-0.47 | $-1.01 | — | — | — | — | — | — | — |
| Total Assets | $4.18M | $8.87M | $3.08M | $7.83M | $13.27M | $2.83M | $2.68M | $2.43M | $2.86M | $566.6K |
| Total Liabilities | $1.57M | $1.21M | $403.9K | $201.4K | $203.3K | $346.0K | $184.5K | $43.6K | $92.3K | $478.9K |
| Shareholders' Equity | $2.99M | $8.04M | $3.04M | $7.95M | $13.27M | $2.48M | $2.49M | $2.39M | $2.77M | $266.0K |
| Cash & Equivalents | — | — | — | $5.81M | $10.92M | $1.29M | $1.29M | $1.73M | $2.53M | $93.4K |
| Operating Cash Flow | -$10.45M | -$4.96M | -$5.88M | -$4.88M | -$3.99M | -$2.62M | -$3.01M | -$2.52M | -$1.55M | -$660.9K |
| Capital Expenditures | $24.6K | $43.0K | $33.7K | $49.2K | — | $0 | $646.2K | — | $0 | $3.1K |
| Shares Outstanding | 19.56M | 15.81M | 8.09M | 5.95M | 5.73M | 3.00M | 78.79M | 75.53M | 67.98M | 51.29M |